INDIANA LABORATORY SYSTEM MONTHLY PARTNER WEBCAST

Thank you for joining us. The webcast will begin shortly.

3/21/2023





Indiana Department of Health INDIANA LABORATORY SYSTEM MONTHLY PARTNER WEBCAST

3/21/2023



- **1. Welcome:** Mark Glazier, division director, biothreat clinical microbiology and environmental virology division
- 2. Laboratory Updates & HAN Updates: Mark Glazier, division director, biothreat clinical microbiology and environmental virology division
- 3. Virology Updates: Brian Pope, division director, virology & serology
- **4. Environmental Microbiology Updates:** Ryan Gentry, division director, environmental microbiology
- 5. IDOH & GCPH Updates: Pam Pontones, deputy health commissioner
- 6. Communicable Disease Rule Updates: Kelly White, director of TB prevention & care, refugee & international health, and NBS/Surveillance
- 7. Q & A: The IDOHL webcast team



IDOH Laboratories

Three ways to stay in the know:

- 1. Email us at <u>IDOH-Lab-</u> <u>Info@health.in.gov</u>
- 2. Sign up for IHAN Indiana Health Alert Network <u>https://ihan-in.org/</u>
- 3. Sign up for laboratory communications at <u>GovDelivery</u>





2023 ILS Webcast Schedule

2nd Wednesdays from 10:30 – 11 a.m.

- 4/12/2023
- 5/20/2023
- 6/21/2023 (3rd Wednesday)
- 7/12/23


- 8/9/23
- 9/13/23
- 10/11/23
 - 11/8/23
- 12/13/23



IDOH Website: Construction Coming Soon







Laboratory Updates Mark Glazier, Division Director, Biothreat – Clinical Microbiology & Environmental Virology



PPE from Langham

- IDOH has quantities of PPE, lab and vaccination supplies available for order, including:
 - Face masks
 - Face shields
 - Gloves
 - Goggles
 - Gowns
 - Respirators, N95s
 - Needles
 - Swabs
 - Infrared Thermometers
 - And More!

Link to access portal: <u>warehouse@elangham.com</u> For portal assistance, please contact <u>Covidsupport@elangham.com</u> or 866-926-3420



2023 Sentinel Clinical Laboratory Certification

- Did your laboratory receive a survey via email for this certification?
- If so, please fill out the emailed survey even if you are not a sentinel laboratory, so we can keep up to date contact information for the laboratories in Indiana
- If your laboratory did not receive an email, please email <u>IDOH-lab-</u> <u>info@health.in.gov</u> to request a survey





APHL Free SAF-T-PAK Training


APHL is offering free SAF-T-PAK Packaging and Shipping Trainings:

- 1) Category A Division 6.2 Infectious Substances LIVE Virtual SEMINARS
 - 13 dates with three different start times
- 2) Category A Division 6.2 Infectious Substances ONLINE SELF-PACED MODULES
 - 11 modules estimated to take approximately eight hours to complete
- 3) Category B ONLINE SELF-PACED MODULES
 - Seven modules estimated to take approximately five hours to complete

If interested, RSVP by completing the following survey at: <u>https://www.surveymonkey.com/r/APHL_SAF_T_PAK_Packing_and_Shipping_2023_IDOHL</u>

*If you have registered for a training, please don't register again just because you're still waiting on confirmation of your registration. It may take a few weeks to receive training registration confirmation.





Virology Updates Brian Pope, Division Director, Virology & Serology



CT/GC Shipping

- Please note: Specimens submitted to IDOHL need to be using the correct shipping labels for the specimens they are submitting.
- Recently, specimens have been shipped in for CT/GC testing under the label for TB testing
 - Specimens are still able to be tested, however they are being paid for another area and specimens are being opened under different BSL conditions as if they were the organism listed on the shipping label.





IHAN: Confirmed Measles Case in KY

- The Indiana Department of Health (IDOH) is alerting clinicians to a report from the Kentucky Department for Public Health of a confirmed case of measles in an individual who attended a large spiritual revival gathering on Feb. 17 and 18 at Asbury University in Wilmore, Kentucky, while contagious. Clinicians are encouraged to remain vigilant for measles, consider travel to Kentucky when evaluating suspected measles cases, and ensure patients remain up to date on recommended measles vaccination. Clinicians should immediately report suspected cases of measles to the IDOH.
- Measles is a highly contagious viral illness. Exposed individuals who do not have evidence of immunity to measles should be encouraged to be vaccinated and should quarantine and monitor for signs and symptoms for 21 days after exposure. Appropriate infection control practices should

Laboratory Testing

 Testing for measles is available through the IDOH Laboratories with prior authorization. To request testing authorization, clinicians and laboratories should contact the IDOH Infectious Disease Epidemiology and Prevention Division at 317-233-7125 during business hours (Monday – Friday, 8:15 a.m. – 4:45 p.m.) or 317-233-1325 after hours.



HAN: Increased Chikungunya Virus Activity in Paraguay and Associated Risk for Travelers

- The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to notify clinicians and public health authorities of an increase in the number of cases of chikungunya reported in Paraguay. Most cases have been reported in the capital district of Asunción and the neighboring Central department.
- As of Feb. 24, 2023, the Ministry of Health in Paraguay reported a total of 71,478 suspect chikungunya cases in Paraguay, with 29,362 of those being probable or confirmed cases since the outbreak began in October 2022 [1]. Further spread of the outbreak in Paraguay and to surrounding countries is possible.
- This Health Advisory provides information on the current status of the chikungunya outbreak in Paraguay and advises on evaluating and testing travelers returning from Paraguay with signs and symptoms consistent with chikungunya virus infection. It also highlights those at increased risk for severe disease and prevention measures to mitigate additional spread of the virus and potential importation into unaffected areas, including the United States.

Laboratory Testing

• Diagnostic testing is available through commercial laboratories, some state health departments, and CDC. Contact your state, territorial, or local health department for more information and to facilitate testing.



Virologic Surveillance

Circulating Influenza Viruses De	etected by IDOF	Laboratory*, Inc	diana, 2022-202	3 Season
	Week 10		Season Total	
PCR Result	Number	Percent of Specimens Received	Number	Percent of Specimens Received
2009 A/H1N1pdm virus	0	0%	8	2%
Influenza A/H3 seasonal virus	0	0%	18	5%
Influenza B Yamagata seasonal virus	0	0%	0	0%
Influenza B Victoria seasonal virus	0	0%	0	0%
Influenza B Virus, genotype pending	0	0%		
Influenza negative	10	100%	340	91%
Inconclusive	0	0%	2	<1%
Unsatisfactory speciment	0	0%	6	2%
Influenza A unsubtypeable	0	0%	0	0%
Influenza Co-infection	0	0%	0	0%
Total	10	100%	374	100%

obtained from the IDOHL via specimens submitted from the ISDH Sentinel Influenza Surveillance System and IN el Laboratories.

:isfactory specimens include specimens that leaked in transit, were too long in transit, or were inappropriately d

-Infection of multiple influenza subtypes has been detected.
 isonal total may include delayed specimens not included in weekly total.

15



Medical Illustrator: Stephanie Rossow



Environmental Microbiology Updates Ryan Gentry, Division Director, Environmental Microbiology

A THINK

Selection March March

A NAVA

HAN: Increase in Extensively Drugresistant *Shigellosis* in the United States

- The Centers for Disease Control and Prevention (CDC) has been monitoring an increase in extensively drug-resistant (XDR) *Shigella* infections (shigellosis) reported through national surveillance systems.
 - In 2022, about 5% of *Shigella* infections reported to CDC were caused by XDR strains, compared with 0% in 2015.
 - XDR *Shigella* strains can spread antimicrobial resistance genes to other enteric bacteria.
 - CDC defines XDR *Shigella* bacteria strains that are resistant to all commonly recommended empiric and alternative antibiotics azithromycin, ciprofloxacin, ceftriaxone, trimethoprim-sulfamethoxazole (TMP-SMX), and ampicillin.



Recommendations for Laboratories

Clinical Laboratories

- Report known or suspected *Shigella* cases to IDOH
 Epidemiology
- Submit all *Shigella* isolates or positive stools to IDOHL





Indiana Department of Health

IDOH AND GPHC UPDATE

PAM PONTONES, MA DEPUTY HEALTH COMMISSIONER OF LOCAL HEALTH SERVICES

03/21/23

HHS: End of the Public Health Emergency

- Department of Health and Human Services (HHS) is planning for the federal Public Health Emergency (PHE) for COVID-19 to expire at the end of the day on May 11 (renewed Feb. 11 for 90 days)
- Since the peak of the Omicron surge at the end of January 2022:
 - Daily COVID-19 reported cases are down 92%
 - COVID-19 deaths have declined by over 80%
 - New COVID-19 hospitalizations are down nearly 80%
- Access to COVID-19 vaccinations and certain treatments, such as Paxlovid and Lagevrio, will generally not be affected
- Partners across the U.S. Government (USG) are developing plans to ensure a smooth transition for the provision of COVID-19 vaccines and treatments as part of the traditional health care marketplace
- Transition to traditional healthcare coverage occurs later this year

https://www.hhs.gov/about/news/2023/02/09/fact-sheet-covid-19-publichealth-emergency-transition-roadmap.html

Indiana Medicaid Reminder



Many Hoosiers could lose their Medicaid benefits because the recent federal spending bill removed Medicaid coverage protections from the federal public health emergency. Taking action now could help you stay covered.

Take action now to keep health care coverage!

During the federal public health emergency, no one lost their Medicaid coverage. Because Medicaid coverage protections are no longer included in the federal public health emergency, redetermination actions will begin in April 2023. Many Hoosiers could lose their benefits and now is the time to take action to help you stay covered.

Is your address correct? What is your income? To help you have the right health coverage, Indiana Family and Social Services Administration needs all Medicaid members to take these steps to ensure we have current info.

- Go to FSSABenefits.IN.gov
- Scroll down to the "Manage Your Benefits" section
- Click on "Sign in to my account" or "Create account"

Watch your mail! Be sure to respond with any info you're asked for. Need help updating your address? Call 800-403-0864.





Check Your Coverage (in.gov)

TB Summit



Join the Indiana Department of Health for an educational forum on tuberculosis during **Indiana's World TB Day Celebration on March 23, 2023**.

REGISTER NOW

https://www.intbsummit.com/



https://www.intbsummit.com/

Infectious Disease Summit



- We're excited to announce the date for the 2023 Infectious Disease Summit!
- Save the date for May 9-10, at the Renaissance North Hotel in Carmel
- Join together to Calibrate, Collaborate, and Respond
- Registration opens in soon
- Visit **www.infectiousdiseasesummit.com** for more information





INDIANA GOVERNOR'S PUBLIC HEALTH COMMISSION







GPHC: Senate Bill 4

- Defines core public health services that should be available in every county
- For counties that decide to opt-in to additional funding, local health departments will be responsible for ensuring core services are provided in their county and serve as the local convener of community partners
- Provides flexibility for staff LHDs could employ to carry out their duties so long as the required core services are delivered per statute
- Outlines local health officer qualifications and updated health board membership
- And more ...



House Bill 1001 (budget bill)

- Increases the state's investment in public health infrastructure
- Provides local health departments with additional, stable, recurring funding by increasing the annual state appropriation to local health departments from \$6.9M per year to \$200M per year (increase on average of approximately \$30 per capita).
- Repeals the Indiana Local Health Department Trust Account and repurposes the Local Health Maintenance Fund to consolidate state funds for local health departments into a single fund
- Accountability and transparency
- Core public health services
- And more ...



GPHC Legislative Updates

Senate Bill 4

- Successfully passed out of the Senate, vote 41-7.
- Heard in House Public Health Committee on 3/14 and held for amend and vote in the next week or two.

House Bill 1001

- Passed out of the House
 - Made changes to our funding request for counties and regional support
- Hearings and discussions ongoing in Senate Appropriations
 - Will not move until toward the end of session
 - Will end in conference committee





Indiana Department of Health INDIANA COMMUNICABLE DISEASE REPORTING UPDATES

March 2023

Indiana Communicable Disease Rule Changes

- Streamlined timeframes for reporting
 - Immediately
 - Within one working day
- Updated reportable disease list for hospitals/providers as well as a reportable result/pathogen list for laboratories
- Changes effective April 1



Indiana Communicable Disease Rule Changes

2023 Indiana Reportable Disease List

- **Audience:** Healthcare providers and hospitals
- Lists the name of reportable <u>diseases/conditions</u>

2023 Indiana Reportable Result/Pathogen List

- Audience: Laboratorians
- Lists the name of reportable
 pathogens/organisms



2023 Indiana Reportable Disease List for Healthcare Providers and Hospitals

410 IAC 1-2.5-75 & 76

REPORT IMMEDIATELY ON SUSPICION

Anthrax Botulism Cholera (Vibrio cholerae O1, O139, or toxigenic) Diphtheria Eastern equine encephalitis virus (EEEV) disease Hemolytic uremic syndrome (HUS), postdiarrheal Hepatitis, viral, Type B, pregnant woman (acute and chronic) or perinatally exposed infant Influenza A, Novel Measles (Rubeola) Melioidosis (Burkholderia pseudomallei) Meningococcal disease, invasive Middle East Respiratory Syndrome (MERS) Plague Poliomyelitis

Rabies, human Rubella (German Measles) Rubella congenital syndrome Severe Acute Respiratory Syndrome (SARS) Smallpox (Variola infection) Tularemia Viral hemorrhagic fever, filoviruses Ebola virus Marburg virus Viral hemorrhagic fever, other Crimean-Congo hemorrhagic fever virus Guanarito virus Junin virus Lassa virus Luio virus Machupo virus Sabia virus

TO REPORT:

 Immediately Reportable; complete steps 1-2 Within One Working Day: complete step 2

Indiana

Health

Step 1: Call 317-233-7125 317-233-1325 (After hours) Step 2:



 NBS users: Report conditions via Morbidity Report in NBS - Non-NBS users: Report with this form

2023 Indiana Reportable Disease List for Healthcare Providers and Hospitals



IMMEDIATELY REPORTABLE OUTBREAKS

- 1. Any disease required to be reported as listed above
- 2. Newborns with diarrhea in hospitals or other institutions
- 3. Foodborne or waterborne diseases in addition to those specified above
- 4. Streptococcal illnesses
- 5. Conjunctivitis
- 6. Impetigo
- 7. Clusters or suspected outbreaks of any disease associated with hospitals and healthcare facilities
- 8. Influenza-like illness
- 9. Viral meningitis
- 10. Unusual occurrence of disease
- 11. Any disease (e.g. anthrax, plague, tularemia, Brucella species, smallpox, or botulism) or chemical illness considered a bioterrorism threat, importation, or laboratory release

OTHER REPORTABLE NON-COMMUNICABLE CONDITIONS AND DISEASES

- Report all blood lead results (capillary and venous) in children and adults within one week (410 IAC 29-3-1)
- · Report confirmed cases of cancer occurring in residents diagnosed or treated in Indiana to the state cancer registry (410 IAC 21-1-2)

REPORT WITHIN ONE WORKING DAY

Acquired Immunodeficiency Syndrome (AIDS) Acute Flaccid Myelitis (AFM) Anaplasmosis Animal bite or exposure Arboviral disease or infection, domestic West Nile virus (WNV) St. Louis encephalitis virus (SLEV) Western equine encephalitis virus (WEEV) California serogroup viruses (La Crosse virus (LACV), Jamestown Canyon virus (JCV)), Powassan virus (POWV) Arboviral disease or infection, imported Chikungunya virus (CHIKV) Dengue virus (DENV) Zika virus (ZIKV) Babesiosis Brucellosis Campylobacteriosis Candida auris and unusual Candida spp. (species other than C. albicans. C. parapsilosis, C. dubliniensis, C. lusitaniae, C. tropicalis or C. krusei) Carbapenemase-Producing Organisms (CPO) Chancroid Chlamydia trachomatis, genital infection Lymphogranuloma venerum Coccidioidomycosis COVID-19, cases and deaths Cryptosporidiosis Cyclosporiasis Ehrlichiosis Escherichia coli (E. coli) infection (Shiga toxinproducing E. coli (STEC)) including. but not limited to, E. coli O157 and other serogroups)

Giardiasis Gonorrhea Disseminated gonococcal infection Granuloma inguinale Haemophilus influenzae, invasive disease. (including antimicrobial susceptibility testing) Hansen's disease (leprosy) Hantavirus infection (pulmonary and non-pulmonary), including, but not limited to: Sin Nombre virus Seoul virus Hepatitis, viral, Type A Hepatitis, viral, Type B (acute and chronic) Hepatitis, viral, Type C (acute and chronic) Hepatitis, viral, Type C, pregnant woman (acute or chronic) or perinatally exposed infant Hepatitis, viral, Type Delta Hepatitis, viral, Type E Hepatitis, viral, unspecified Histoplasmosis HIV infection/disease HIV infection/disease, pregnant woman or perinatally exposed infant Influenza-associated death (all ages) Japanese encephalitis Latent tuberculosis infection (LTBI) Legionellosis Leptospirosis Listeriosis Lyme disease Lymphocytic choriomeningitis virus Malaria Mpox (formerly known as Monkeypox) Multisystem Inflammatory Syndrome in adults (MIS-A)

Multisystem Inflammatory Syndrome in children (MIS-C) Mumps Pandrug-resistant Organisms

Pertussis Psittacosis Q Fever Rabies, postexposure prophylaxis administration Salmonellosis, non-typhoidal Shigellosis Spotted fever rickettsiosis, including Rocky Mountain Spotted fever Streptococcus pneumoniae, invasive disease (including antimicrobial susceptibility testing) Streptococcus, Group A, invasive disease Syphilis Tetanus Toxic shock syndrome (streptococcal or staphylococcal) Trichinellosis Tuberculosis disease, cases and suspects Typhoid and paratyphoid fever, cases and carriers Vancomycin-resistant Staphylococcus oureus (VRSA) and Vancomycin intermediate Staphylococcus oureus (VISA) Varicella (chickenpox) Vibriosis (non-cholera Vibrio infection) Yellow fever Yersiniosis, Non-pestis

2023 Indiana Reportable **Result/Pathogen List for Laboratories** 410 IAC 1-2.5-75 & 76



REPORT IMMEDIATELY UPON SUSPICION

Bacillus anthracis			
Burkholderia mallei			
Burkholderia pseudomallei			
Clostridium botulinum			
Corynebacterium diphtheriae			
Eastern equine encephalitis virus			
Francisella tularensis			
Hepatitis, viral, type B, pregnant woman (acute			
and chronic) or perinatally exposed infant †			
Measles virus			
Middle East Respiratory Syndrome Coronavirus			
(MERS-CoV)			
Neisseria meningitidis, invasive disease			
Novel influenza A			
Poliovirus			
Rabies virus			

SARS-associated coronavirus (SARS-CoV) Smallpox (variola) virus Viral hemorrhagic fever, filoviruses Ebola virus Marburg virus Vibrio cholerae O1, O139, or toxigenic Viral hemorrhagic fever, other Crimean-Congo hemorrhagic fever virus Guanarito virus Junin virus Lassa virus Lujo virus Machupo virus Sabia virus Yersinia pestis

Rubella virus

For immediate reporting call: 317-233-7125 or 317-233-1325 (after hours)

Please also report via electronic laboratory reporting.

For facilities unable to submit via ELR please fax reports to 317-234-2812.

REPORT WITHIN ONE WORKING DAY

Anaplasma spp. Arboviruses including, but not limited to: Chikungunya virus Dengue virus Jamestown Canyon virus Japanese encephalitis virus La Crosse (California serogroup) viruses Powassan virus St. Louis encephalitis virus Western equine encephalitis virus West Nile virus Zika virus Babesia spp. Bordetella pertussis Borrelia buradorferi Brucella spp. Campylobacter spp. Candida auris and unusual Candida spp. (Species other than C. albicans, C. parapsilosis, C. dubliniensis, C.lusitaniae, C. tropicalis, or C. krusei) Carbapenemase-producing Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii* Chlamydia psittaci Chlamydia trachomatis Lymphogranuloma venereum (LGV) (C. trachomatis serotypes L1, L2, or L3) Clostridium tetani Coccidioides spp Coxiella burnetii Cryptosporidium spp. Cyclospora cayetanensis * Include antimicrobial susceptibility testing

Ehrlichia spp. Escherichia coli (E. coli) infection (Shiga toxin-producing (STEC), including but not limited to, E. coli O157, E. coli O157:H7, non-O157 E. coli, and Shiga toxin detected* Giardia spp. Grimontia hollisae (Vibrio hollisae) Haemophilus ducrevi Haemophilus influenzae, invasive disease* Hantavirus Hepatitis, viral, Type A, Anti-HAV IgM or RNA detected Hepatitis, viral, Type B¹ Hepatitis, viral, Type C Hepatitis, viral, Type Delta Hepatitis, viral, Type E, Anti-HEV IgM and IgG Hepatitis, viral, unspecified Histoplasma capsulatum HIV and related retroviruses Influenza Interferon gamma release assay (IGRA) for tuberculosis (positive results only) Legionella spp. Leptospira spp. Listeria monocytogenes Lymphocytic choriomeningitis virus Mpox (Monkeypox) virus, including Nonvariola Orthopox virus and Orthopox virus Mumps virus Mycobacterium leprae Mycobacterium tuberculosis

Neisseria gonorrhoeae (list anatomic site to determine if disseminated infection)* Pandrug-resistant Organisms Photobacterium damselae (Vibrio damsela) Plasmodium spp. Pneumocystis carinii (Pneumocystis pneumonia) Rickettsia (non-rickettsii spp.) Rickettsia rickettsii Salmonella spp. (non-typhoidal) Salmonella serotype Paratyphi (Paratyphoid fever)* Salmonella serotype Typhi (Typhoid fever)* SARS-CoV-2 Shigella spp. Streptococcus, group A (Streptococcus pyogenes), invasive disease* Streptococcus pneumoniae, invasive disease* Treponema pallidum Trichinella spiralis Vancomycin-resistant Staphylococcus aureus (VRSA) and Vancomycin intermediate Staphylococcus aureus (VISA)* Varicella-zoster virus Vibrio spp. West African monkeypox virus Yellow fever virus Yersinia spp., Enterocolitica, Pseudotuberculosis

2023 Indiana Reportable **Result/Pathogen List for Laboratories** 410 IAC 1-2.5-75 & 76



HEPATITIS C ONE DAY ISOLATE SUBMISSION

Positive Anti-HCV (including rapid tests);

including quantitative, qualitative, and

Negative Anti-HCV results for children

If any of the above results are reported.

2. Concurrent ALT and total bilirubin result

3. Other associated positive or negative

hepatitis serological results (e.g.,

hepatitis D, and/or hepatitis E)

REPORTING REQUIREMENTS

Reporting is required of any specimen

derived from the human body yielding

microscopic, bacteriologic, immunologic,

serologic, or other evidence of infection

by any of the organisms or agents listed.

1. Test: Name, date, test results, specimen

source, normal limits for the test, test

result interpretation, and laboratory's

accession number or other numeric

2. Person: Name, address, and date of

telephone number of attending

physician, hospital, clinic, or other

3. Submitter: Name, address, and

specimen submitter

birth (or age if date of birth is not

hepatitis A, hepatitis B, hepatitis C,

• HCV RNA (positive/detectable and

negative/undetectable results),

genotype testing;

1. Pregnancy status

≤ 36 months of age; and

also report the following:

Positive HBsAa;

HEPATITIS B

- Positive/detectable HBV DNA (including quantitative, qualitative,
- and genotype testing);
- · Positive anti-HBc IgM; Positive HBeAg; · Anti-HBs (positive, negative, and
- indeterminate) for children ≤ 2 years of age: and • If any of the above results are
- reported, also report the following:
- 1. Pregnancy status
- 2. Concurrent ALT and total bilirubin result
- 3. Other associated positive or negative hepatitis serological results (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, and/or hepatitis E)
- 4. Negative HBsAg and/or negative/ undetectable HBV DNA results

HEPATITIS D

· Positive hepatitis D antibody testing; and

also report the following:

- Positive HDV RNA (including) quantitative and qualitative) · If any of the above results are reported,
- 1. Pregnancy status
- 2. Concurrent ALT and total bilirubin result

Any infection, disease or condition submitted via electronic laboratory reporting should continue to be reported to the Indiana Department of Health. For facilities unable to submit via ELR please fax reports to 317-234-2812.

4. Laboratory: Name, address, telephone number, and CLIA ID number of the laboratory performing the test

identifier.

available)

When submitting organisms and for questions about isolate submission. Indiana Department of Health Laboratory should be notified at

317-921-5500.

Laboratories shall submit all suspect biothreat isolates of the following organisms to the IDOH Laboratory for further evaluation within one (1) business day of isolation:

- 1. Bacillus anthracis
- 2. Brucella spp.
- 3. Burkholderia mallei/pseudomallei
- 4. Francisella tularensis Yersinia pestis 5.

THREE DAY ISOLATE SUBMISSION

Laboratories shall submit all isolates of the following organisms to the IDOH Laboratory for further evaluation within three (3) business days of isolation:

- 1. Carbapenemase-producing Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii
- 2. Candida auris and unusual Candida spp. (Species other than C. albicans, C. parapsilosis, C. dubliniensis, C. lusitaniae, C. tropicalis, or C. krusei)
- 3. Escherichia coli (Shiga toxin-producing E. coli (STEC)) isolates*
- 4. Haemophilus influenzae, invasive disease
- 5. Arboviral IgM positive CSF or serum specimens, including Eastern Equine Encephalitis virus
- 6. Listeria monocytogenes
- 7. Mycobacterium tuberculosis complex (M. tuberculosis. M. bovis. M. canettii. M. africanum, M. microti)
- 8. Neisseria meningitidis, invasive disease
- 9. Salmonella spp. isolates*
- 10. Shigella spp. isolates*
- 11. Streptococcus pneumoniae, invasive disease, isolates from persons less than five (5) years of age
- 12. Vibrio cholerae isolates*
- 13. Vibrio spp., Grimontia hollisae (Vibrio hollisae), and Photobacterium damselae (Vibrio damsela) isolates*
- 14. Vancomycin-resistant Staphylococcus aureus (VRSA) and Vancomycin intermediate Staphylococcus aureus (VISA). Staphylococcus aureus isolated from any body site that are vancomycin intermediate level MIC = 4-8 µg/mL or vancomycin resistant level MIC >= 16 μ g/mL

* If isolate of organism is not available, submit clinical specimens per IAC 1-2.5-76(f) 3/1/23

⁺ Further guidance on the second page of the Indiana Reportable Result/Pathogen List for Laboratories

Reportable Result/Pathogen List Changes – Immediately Reportable

Results/pathogens that are newly immediately reportable

- Burkholderia mallei
- Burkholderia pseudomallei
- Eastern equine encephalitis virus
- Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
- Neisseria meningitidis, invasive disease
- Poliovirus
- Rabies virus
- SARS-associated coronavirus (SARS-CoV)

- Viral hemorrhagic fever, filoviruses
 - Ebola virus
 - Marburg virus
- Viral hemorrhagic fever, arenaviruses
 - Crimean-Congo hemorrhagic fever virus
 - Guanarito virus
 - Junin virus
 - Lassa virus
 - Lujo Virus
 - Machupo virus
 - Sabia virus



Result/Pathogen Reporting – Within One Working Day

- All pathogens previously reportable within 24 hours, 72 hours, or 5 business days are now reportable within one working day
- Changes also include some pathogens that were previously immediately reportable

Summary of Changes

- Several pathogens were added
- Two pathogens previously reportable were modified in scope
- Arboviruses were re-grouped to be listed together under arboviruses rather than by individual name, with the exception of Eastern Equine Encephalitis Virus (EEEV)
- One pathogen is no longer reportable



Result/Pathogen Reporting List Changes – Within One Working Day

No Longer Reportable

• Typhus, endemic (flea-borne)

Reporting Scope Adjustments

- Carbapenemase-producing Organisms (CPO)
 - Previously only CP-CRE was reportable
 - Disease has been expanded to include
 - Acinetobacter baumannii
 - Pseudomonas aeruginosa
- Vancomycin-resistant Staphylococcus aureus (VRSA) and Vancomycin intermediate Staphylococcus aureus (VISA)
 - Previously Staphylococcus aureus, vancomycin resistance level of MIC ≥ 8 µg/mL or severe Staphylococcus aureus in a previously healthy person

Isolate Submissions – Within One Working Day

The following isolates must be sent to IDOH Laboratory for further evaluation within one working day

- Bacillus anthracis
- Brucella spp.
- Burkholderia mallei/pseudomallei
- Francisella tularensis
- Yersinia pestis



Isolate Submissions – Within 3 Business Days Changes

- Two new pathogen isolates have been added to the list
 - *Candida auris* and unusual *Candida* spp.
 - (Species other than C. albicans, C. parapsilosis, C. dubliniensis, C. lusitaniae, C. tropicalis, or C. krusei)
 - o Arboviral IgM positive CSF or serum specimens, including Eastern Equine Encephalitis virus
- Three pathogens listed have been expanded
 - Mycobacterium tuberculosis has been expanded to include Mycobacterium tuberculosis complex pathogens (M. tuberculosis, M. bovis, M. canettii, M. africanum, M. microti)
 - Carbapenamase procucing- carbapenem resistant Enterobacteriaceae (CP-CRE) has been expanded to Carbapenemase-producing *Enterobacterales*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*
 - Staphylococcus aureus, vancomycin resistance level of MIC \ge 8 µg/mL has been expanded to
 - Vancomycin-resistant *Staphylococcus aureus* (VRSA) and Vancomycin intermediate *Staphylococcus aureus* (VISA)
 - Staphylococcus aureus isolated from any body site that are vancomycin intermediate level MIC = $4-8 \mu g/mL$ or vancomycin resistant level MIC > = $16 \mu g/mL$



Isolate Submissions – Within Three Business Days

Isolates for the following organisms must be submitted to IDOH Laboratory for further evaluation within three business days of isolation:

- Carbapenemase-producing Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii
- Candida auris and unusual Candida spp. (Species other than C. albicans, C. parapsilosis, C. dubliniensis, C. lusitaniae, C. tropicalis, or C. krusei)
- Escherichia coli (Shiga toxin-producing E. coli (STEC)) isolates[‡]
- Haemophilus influenzae, invasive disease
- Arboviral IgM positive CSF or serum specimens, including Eastern Equine Encephalitis virus
- Listeria monocytogenes

Indiana

Health

- Mycobacterium tuberculosis complex (M. tuberculosis, M. bovis, M. canettii, M. africanum, M. microti)
- Neisseria meningitidis, invasive disease
- Salmonella spp. isolates[‡]
- *Shigella* spp. isolates[‡]
- *Streptococcus pneumoniae*, invasive disease, isolates from persons less than five (5) years of age
- Vibrio cholerae isolates‡
- Vibrio spp., Grimontia hollisae (Vibrio hollisae), and Photobacterium damselae (Vibrio damsela) isolates‡
- Vancomycin-resistant Staphylococcus aureus (VRSA) and Vancomycin intermediate Staphylococcus aureus (VISA). Staphylococcus aureus isolated from any body site that are vancomycin intermediate level MIC = 4-8 μg/mL or vancomycin resistant level MIC > = 16 μ g/mL

Reporting Hepatitis B, C, &

Page 2 of the reportable/pathogens list includes additional information about reporting Hepatitis B, C, & D.

HEPATITIS B

Positive HBsAq:

- Positive/detectable HBV DNA (including quantitative, qualitative, and genotype testing);
- Positive anti-HBc IgM;
- Positive HBeAg;
- Anti-HBs (positive, negative, and indeterminate) for children ≤ 2 years
- of age: and
- · If any of the above results are reported, also report the following:

1. Pregnancy status

and

- Concurrent ALT and total bilirubin result
- 3. Other associated positive or negative hepatitis serological results (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, and/or hepatitis E)
- 4. Negative HBsAg and/or negative/ undetectable HBV DNA results

submit via ELR please fax reports to

317-234-2812.

Positive Anti-HCV (including rapid tests);

- HCV RNA (positive/detectable and negative/undetectable results), including quantitative, qualitative, and
- genotype testing; Negative Anti-HCV results for children
- ≤ 36 months of age; and If any of the above results are reported,
- also report the following:

Pregnancy status

HEPATITIS C

- 2. Concurrent ALT and total bilirubin result
- 3. Other associated positive or negative hepatitis serological results (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, and/or hepatitis E)

HEPATITIS D REPORTING REQUIREMENTS Positive hepatitis D antibody testing; Reporting is required of any specimen derived from the human body yielding Positive HDV RNA (including) microscopic, bacteriologic, immunologic, quantitative and qualitative) serologic, or other evidence of infection · If any of the above results are reported, by any of the organisms or agents listed. also report the following: 1. Test: Name, date, test results, specimen 1. Pregnancy status source, normal limits for the test, test result interpretation, and laboratory's 2. Concurrent ALT and total bilirubin result accession number or other numeric identifier. Any infection, disease or condition 2. Person: Name, address, and date of birth (or age if date of birth is not submitted via electronic laboratory available) reporting should continue to be 3. Submitter: Name, address, and reported to the Indiana Department telephone number of attending of Health. For facilities unable to

- physician, hospital, clinic, or other specimen submitter
- 4. Laboratory: Name, address, telephone number, and CLIA ID number of the laboratory performing the test

When submitting organisms and for questions about isolate submission. Indiana Department of Health Laboratory should be notified at 317-921-5500.

39



Expected Impacts of Reporting Changes

- Simplified disease/pathogen reporting timeframes for healthcare providers and laboratorians
- Allows the IDOH to easily change and update reportable diseases
- Increased reporting guidance for healthcare providers and laboratorians
- No impact to reporting methods (i.e., NBS, Confidential Report of Communicable Diseases)



How to Report Results/Pathogens to the IDOH

Immediately Reportable

1. Call 317-233-7125 or 317-233-1325 (After hours)

<u>AND</u>

2. Electronic Lab Report or fax result to 317-234-2812 Within One Working Day

Electronic Lab Report **OR**

Fax result to 317-234-2812



Additional Laboratory Information

Notify Indiana Department of Health Laboratory when:

- Submitting Organisms, or with questions about isolate submission.
- Call 317-921-5500 to reach the IDOH Laboratory

Electronic Laboratory Reporting

- Any infection, disease or condition submitted via electronic laboratory reporting should continue to be reported to the Indiana Department of Health.
- Facilities unable to submit via ELR please fax results to **317-234-2812**.



Timeline for Reporting Changes

- The following documents were released in early March
 - Indiana Reportable Disease List for Healthcare Providers and Hospitals
 - o Indiana Reportable Result/Pathogen List for Laboratories
 - Indiana Health Alert Network message
 - Frequently asked questions document
- The changes will be effective starting **April 1**
- The released documents can be found at the following URL:
 - <u>https://www.in.gov/health/erc/infectious-disease-epidemiology/infectious-disease-epidemiology/communicable-disease-reporting/</u>



Questions?

CONTACT:


IDOH Laboratory Email: <u>IDOH-lab-info@health.in.gov</u> Laboratory Main Phone Line: 317-921-5500



Next Webcast

The next Indiana Laboratory System webcast is scheduled for:

Date: Wednesday, April 12 Time: 10:30 – 11 a.m.





Indiana Department of Health



THANK YOU FOR JOINING THE WEBCAST!

- IDOH Laboratory Team